Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials
Authors
Keywords
Glioblastoma, GBM, Response Assessment, T1 Subtraction, RANO
Journal
Neurotherapeutics
Volume 14, Issue 2, Pages 307-320
Publisher
Springer Nature
Online
2017-01-20
DOI
10.1007/s13311-016-0507-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Contrast-enhancing tumor growth dynamics of preoperative, treatment-naive human glioblastoma
- (2016) Benjamin M. Ellingson et al. CANCER
- The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab
- (2015) R. Y. Huang et al. CLINICAL CANCER RESEARCH
- Patient and treatment factors associated with survival among adult glioblastoma patients: A USA population-based study from 2000–2010
- (2015) I-Wen Pan et al. JOURNAL OF CLINICAL NEUROSCIENCE
- CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012
- (2015) Quinn T. Ostrom et al. NEURO-ONCOLOGY
- An extent of resection threshold for recurrent glioblastoma and its risk for neurological morbidity
- (2014) Mark E. Oppenlander et al. JOURNAL OF NEUROSURGERY
- Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma
- (2014) Matthew M. Grabowski et al. JOURNAL OF NEUROSURGERY
- Impact of imaging measurements on response assessment in glioblastoma clinical trials
- (2014) D. A. Reardon et al. NEURO-ONCOLOGY
- Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD)
- (2014) Patrick Y. Wen et al. NEURO-ONCOLOGY
- Pros and cons of current brain tumor imaging
- (2014) B. M. Ellingson et al. NEURO-ONCOLOGY
- Progression types after antiangiogenic therapy are related to outcome in recurrent glioblastoma
- (2014) M. Nowosielski et al. NEUROLOGY
- Time window for postoperative reactive enhancement after resection of brain tumors: less than 72 hours
- (2014) Stephanie Lescher et al. Neurosurgical Focus
- A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
- (2014) Mark R. Gilbert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
- (2014) Olivier L. Chinot et al. NEW ENGLAND JOURNAL OF MEDICINE
- When Gross Total Resection of a Glioblastoma Is Possible, How Much Resection Should Be Achieved?
- (2014) Kaisorn L. Chaichana et al. World Neurosurgery
- Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma
- (2013) Kaisorn L. Chaichana et al. NEURO-ONCOLOGY
- Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study
- (2013) J. L. Boxerman et al. NEURO-ONCOLOGY
- Identifying the mesenchymal molecular subtype of glioblastoma using quantitative volumetric analysis of anatomic magnetic resonance images
- (2013) Kourosh M. Naeini et al. NEURO-ONCOLOGY
- Recurrent Glioblastoma Treated with Bevacizumab: Contrast-enhanced T1-weighted Subtraction Maps Improve Tumor Delineation and Aid Prediction of Survival in a Multicenter Clinical Trial
- (2013) Benjamin M. Ellingson et al. RADIOLOGY
- Probabilistic Radiographic Atlas of Glioblastoma Phenotypes
- (2012) B.M. Ellingson et al. AMERICAN JOURNAL OF NEURORADIOLOGY
- Relationship between Tumor Enhancement, Edema,IDH1Mutational Status,MGMTPromoter Methylation, and Survival in Glioblastoma
- (2012) J.A. Carrillo et al. AMERICAN JOURNAL OF NEURORADIOLOGY
- Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria
- (2012) J. G. Perez-Larraya et al. NEURO-ONCOLOGY
- Standards of care for treatment of recurrent glioblastoma—are we there yet?
- (2012) Michael Weller et al. NEURO-ONCOLOGY
- Pseudoprogression and Pseudoresponse: Imaging Challenges in the Assessment of Posttreatment Glioma
- (2011) L.C. Hygino da Cruz et al. AMERICAN JOURNAL OF NEURORADIOLOGY
- An extent of resection threshold for newly diagnosed glioblastomas
- (2011) Nader Sanai et al. JOURNAL OF NEUROSURGERY
- Bevacizumab and Irinotecan in the Treatment of Recurrent Malignant Gliomas
- (2010) John F. de Groot et al. CANCER JOURNAL
- Validation and Simplification of the Radiation Therapy Oncology Group Recursive Partitioning Analysis Classification for Glioblastoma
- (2010) Jing Li et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
- (2010) Patrick Y. Wen et al. JOURNAL OF CLINICAL ONCOLOGY
- Radiographic patterns of relapse in glioblastoma
- (2010) Marc C. Chamberlain JOURNAL OF NEURO-ONCOLOGY
- Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 2004
- (2010) L. Bauchet et al. NEURO-ONCOLOGY
- Bidimensional Measurements in Brain Tumors: Assessment of Interobserver Variability
- (2009) James M. Provenzale et al. AMERICAN JOURNAL OF ROENTGENOLOGY
- End Point Assessment in Gliomas: Novel Treatments Limit Usefulness of Classical Macdonald's Criteria
- (2009) Martin J. van den Bent et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
- (2009) Henry S. Friedman et al. JOURNAL OF CLINICAL ONCOLOGY
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
- (2009) Roger Stupp et al. LANCET ONCOLOGY
- Glioma vascularity correlates with reduced patient survival and increased malignancy
- (2009) Stephen M. Russell et al. SURGICAL NEUROLOGY
- Brain Tumor Imaging in Clinical Trials
- (2008) J.W. Henson et al. AMERICAN JOURNAL OF NEURORADIOLOGY
- Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors
- (2008) Felix Bokstein et al. CANCER
- Tumor Angiogenic and Hypoxic Profiles Predict Radiographic Response and Survival in Malignant Astrocytoma Patients Treated With Bevacizumab and Irinotecan
- (2008) Sith Sathornsumetee et al. JOURNAL OF CLINICAL ONCOLOGY
- Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety
- (2008) Tyler Y. Kang et al. JOURNAL OF NEURO-ONCOLOGY
- Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan
- (2008) R. M. Zuniga et al. JOURNAL OF NEURO-ONCOLOGY
- Time course of imaging changes of GBM during extended bevacizumab treatment
- (2008) Suchitra Ananthnarayan et al. JOURNAL OF NEURO-ONCOLOGY
- Independent association of extent of resection with survival in patients with malignant brain astrocytoma
- (2008) Matthew J. McGirt et al. JOURNAL OF NEUROSURGERY
- Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas
- (2008) Kathleen R. Lamborn et al. NEURO-ONCOLOGY
- Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence
- (2008) A. D. Norden et al. NEUROLOGY
- Relationship between Gene Expression and Enhancement in Glioblastoma Multiforme: Exploratory DNA Microarray Analysis
- (2008) Whitney B. Pope et al. RADIOLOGY
- Response criteria for glioma
- (2008) A Gregory Sorensen et al. Nature clinical practice. Oncology
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started